Related Experiment Video
Updated: Feb 19, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Buprenorphine in Neonatal Abstinence Syndrome
1Sidney Kimmel Medical College of Thomas Jefferson University, Department of Pharmacology and Experimental Medicine, Philadelphia, Pennsylvania, USA.
Abstract:
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Abuse and Addiction: Pharmacological Phenomena
Analgesia and Pain Management
Drug Dependence
Pharmaceutical Poisoning: Treatment Strategies

